CN103813784A - 控释鼻腔睾酮凝胶、用于经鼻给药的方法和预充式多剂量施药器系统 - Google Patents

控释鼻腔睾酮凝胶、用于经鼻给药的方法和预充式多剂量施药器系统 Download PDF

Info

Publication number
CN103813784A
CN103813784A CN201280035162.8A CN201280035162A CN103813784A CN 103813784 A CN103813784 A CN 103813784A CN 201280035162 A CN201280035162 A CN 201280035162A CN 103813784 A CN103813784 A CN 103813784A
Authority
CN
China
Prior art keywords
testosterone
gel
intranasal
testosterone gel
intranasal testosterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280035162.8A
Other languages
English (en)
Chinese (zh)
Inventor
W·克雷普聂
S·福加尔蒂
W·奥别瑞吉尔
P·J·P·M·梅斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aiseersi Pharmaceutical Co Ltd
Original Assignee
Trimel Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimel Pharmaceuticals Corp filed Critical Trimel Pharmaceuticals Corp
Priority to CN201910982324.2A priority Critical patent/CN110613679A/zh
Publication of CN103813784A publication Critical patent/CN103813784A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280035162.8A 2011-05-15 2012-05-15 控释鼻腔睾酮凝胶、用于经鼻给药的方法和预充式多剂量施药器系统 Pending CN103813784A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910982324.2A CN110613679A (zh) 2011-05-15 2012-05-15 控释鼻腔睾酮凝胶、用于经鼻给药的方法和预充式多剂量施药器系统

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161486324P 2011-05-15 2011-05-15
US61/486,324 2011-05-15
US201161486634P 2011-05-16 2011-05-16
US61/486,634 2011-05-16
PCT/IB2012/001127 WO2012156822A1 (en) 2011-05-15 2012-05-15 Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910982324.2A Division CN110613679A (zh) 2011-05-15 2012-05-15 控释鼻腔睾酮凝胶、用于经鼻给药的方法和预充式多剂量施药器系统

Publications (1)

Publication Number Publication Date
CN103813784A true CN103813784A (zh) 2014-05-21

Family

ID=46579248

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201280035162.8A Pending CN103813784A (zh) 2011-05-15 2012-05-15 控释鼻腔睾酮凝胶、用于经鼻给药的方法和预充式多剂量施药器系统
CN201280035150.5A Expired - Fee Related CN103796636B (zh) 2011-05-15 2012-05-15 鼻内睾酮生物粘合性凝胶制剂及其治疗男性性腺功能减退症的用途
CN201910982324.2A Pending CN110613679A (zh) 2011-05-15 2012-05-15 控释鼻腔睾酮凝胶、用于经鼻给药的方法和预充式多剂量施药器系统
CN201811198846.5A Active CN109481394B (zh) 2011-05-15 2012-05-15 鼻内睾酮生物粘合性凝胶制剂及其治疗男性性腺功能减退症的用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201280035150.5A Expired - Fee Related CN103796636B (zh) 2011-05-15 2012-05-15 鼻内睾酮生物粘合性凝胶制剂及其治疗男性性腺功能减退症的用途
CN201910982324.2A Pending CN110613679A (zh) 2011-05-15 2012-05-15 控释鼻腔睾酮凝胶、用于经鼻给药的方法和预充式多剂量施药器系统
CN201811198846.5A Active CN109481394B (zh) 2011-05-15 2012-05-15 鼻内睾酮生物粘合性凝胶制剂及其治疗男性性腺功能减退症的用途

Country Status (16)

Country Link
EP (3) EP2709588B1 (https=)
JP (9) JP6152092B2 (https=)
KR (10) KR102568894B1 (https=)
CN (4) CN103813784A (https=)
AR (2) AR086409A1 (https=)
AU (11) AU2012257490A1 (https=)
BR (2) BR112013029336B1 (https=)
CA (3) CA2836398C (https=)
DK (1) DK2714006T3 (https=)
EA (1) EA201391701A1 (https=)
ES (1) ES2859784T3 (https=)
IL (2) IL229400A0 (https=)
MX (4) MX2013013369A (https=)
PL (1) PL2714006T3 (https=)
WO (2) WO2012156822A1 (https=)
ZA (2) ZA201309265B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108771622A (zh) * 2018-07-11 2018-11-09 尹振图 一种自闭式针形滴嘴及眼药水瓶
CN110461340A (zh) * 2017-01-20 2019-11-15 马特恩制药股份公司 用于降低暴露于空气污染物的风险的鼻用药物组合物
CN111386119A (zh) * 2017-11-27 2020-07-07 Aska制药株式会社 粉末鼻腔给药制剂
TWI790204B (zh) * 2016-06-02 2023-01-21 加拿大商阿爾宙斯製藥有限公司 鼻用大麻素組成物

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
KR102568894B1 (ko) * 2011-05-15 2023-08-21 에이세러스 바이오파마 인크. 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템
US8971800B2 (en) * 2011-05-31 2015-03-03 Qualcomm Incorporated Methods and apparatus for improving NFC activation and data exchange reporting mechanisms
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2014076569A2 (en) * 2012-11-14 2014-05-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
WO2014093818A2 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US11160751B2 (en) * 2013-10-07 2021-11-02 Antares Pharma, Inc. Hematocrit modulation through needle assisted jet injection of testosterone
WO2015127012A1 (en) * 2014-02-19 2015-08-27 Wotton Paul K Needle assisted jet injection administration of testosterone compositions
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
WO2016123317A1 (en) * 2015-01-28 2016-08-04 Prometheon Pharma, Llc Topical formulations of growth factors
EP4233873A3 (en) * 2015-06-29 2023-10-18 Lyra Therapeutics, Inc. Implantable scaffolds for treatment of sinusitis
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR102015020878B1 (pt) * 2015-08-28 2019-08-27 F B M Ind Farmaceutica Ltda formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona.
ES2949053T3 (es) * 2016-01-07 2023-09-25 Viramal Ltd Composiciones de gel para administración transdérmica para maximizar las concentraciones de fármaco en el estrato córneo y suero, y métodos de uso de las mismas
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
MX2018012967A (es) 2016-04-25 2019-03-06 Koska Family Ltd Sistema de suministro medico.
EP3463375A1 (en) * 2016-06-03 2019-04-10 M Et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
US10764951B2 (en) 2017-06-17 2020-09-01 Lg Electronics Inc. Registration method of user terminal in wireless communication system and apparatus therefor
KR102639913B1 (ko) 2017-11-17 2024-02-23 코스카 패밀리 리미티드 유체 전달 매니폴드를 위한 시스템 및 방법
AU2019215163A1 (en) * 2018-02-02 2020-08-20 Acerus Biopharma Inc. Methods of testosterone therapy
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
US12544511B2 (en) 2018-06-20 2026-02-10 Koska Family Limited Systems and methods for pre-filled dual-chamber medical agent delivery
BR112021007877A2 (pt) 2018-10-26 2021-08-03 Viramal Limited composição em gel mucoadesiva
US20200170962A1 (en) 2018-11-30 2020-06-04 F. Markus Leweke Nasal cannabidiol compositions
EP3659583B1 (en) 2018-11-30 2023-06-07 Viramal Limited A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent
KR20210131305A (ko) * 2018-12-14 2021-11-02 아세러스 바이오파마 인크. 테스토스테론의 활성 에스테르 유도체, 조성물 및 그의 용도
USD1052082S1 (en) 2020-06-01 2024-11-19 Koska Family Limited Sealed fluid container
CN112121049B (zh) * 2020-08-28 2022-02-01 嘉兴市第一医院 顺式阿曲库铵在制备治疗男性性腺功能减退症的药物中的应用
CN116600787A (zh) * 2020-11-19 2023-08-15 阿库西亚医疗有限责任公司 非水性凝胶组合物
GB202307501D0 (en) * 2023-05-19 2023-07-05 Lawley Pharmaceuticals Pty Ltd Process for preparing dispensable testosterone cream

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133352A2 (en) * 2008-04-28 2009-11-05 Diurnal Limited Lipid composition
US20100311707A1 (en) * 2003-11-11 2010-12-09 Claudia Mattern Controlled release delivery system for nasal applications and methods of treatment

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
DE4214953C2 (de) 1992-05-06 1995-05-18 Arrowdean Ltd Arzneimittel zur Erhöhung des Testosteronspiegels
US5756071A (en) 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5576071A (en) 1994-11-08 1996-11-19 Micron Technology, Inc. Method of reducing carbon incorporation into films produced by chemical vapor deposition involving organic precursor compounds
JP2000514065A (ja) * 1997-07-03 2000-10-24 アルザ コーポレイション ドラッグデリバリーディバイスとその製造法
US6319913B1 (en) * 1997-11-10 2001-11-20 Cellegy Pharmaceuticals, Inc. Penetration enhancing and irritation reducing systems
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10064950A1 (de) * 2000-12-23 2002-07-11 Impetus Ag Basel Thixotropes Nasenspray
EP1450739A4 (en) * 2001-10-12 2008-12-17 Cns Inc NASAL MOISTURIZING GEL AND APPLICATOR
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
DK1670433T3 (da) * 2003-10-10 2012-03-12 Ferring Bv Transdermal farmaceutisk formulering til mindskelse af hudrester
CA2591296A1 (en) * 2004-12-09 2006-06-15 Bayer Healthcare Ag Stabilisation of glucocorticoid esters with acids
EP1896038B1 (en) * 2005-06-03 2016-11-09 Acrux DDS Pty Ltd Method and composition for testosterone transdermal delivery
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
CN101099742A (zh) * 2006-07-06 2008-01-09 上海富海科申药业有限公司 能够减少皮肤刺激的睾酮凝胶制剂
WO2008040488A1 (en) * 2006-10-04 2008-04-10 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal application of neurotransmitters
JP2010521519A (ja) * 2007-03-23 2010-06-24 ユニメッド・ファーマシューティカルズ・エルエルシー 小児性腺機能低下症の治療用組成物及び治療方法
US8507467B2 (en) * 2007-09-20 2013-08-13 Shiseido Company, Ltd. Transdermally absorbable preparation
PL2500062T3 (pl) * 2007-11-13 2015-12-31 Curadis Gmbh Steroidy C-19 do określonych zastosowań terapeutycznych
KR102568894B1 (ko) * 2011-05-15 2023-08-21 에이세러스 바이오파마 인크. 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100311707A1 (en) * 2003-11-11 2010-12-09 Claudia Mattern Controlled release delivery system for nasal applications and methods of treatment
WO2009133352A2 (en) * 2008-04-28 2009-11-05 Diurnal Limited Lipid composition

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI790204B (zh) * 2016-06-02 2023-01-21 加拿大商阿爾宙斯製藥有限公司 鼻用大麻素組成物
CN110461340A (zh) * 2017-01-20 2019-11-15 马特恩制药股份公司 用于降低暴露于空气污染物的风险的鼻用药物组合物
CN111386119A (zh) * 2017-11-27 2020-07-07 Aska制药株式会社 粉末鼻腔给药制剂
CN108771622A (zh) * 2018-07-11 2018-11-09 尹振图 一种自闭式针形滴嘴及眼药水瓶
CN108771622B (zh) * 2018-07-11 2022-01-07 尹振图 一种自闭式针形滴嘴及眼药水瓶

Also Published As

Publication number Publication date
IL229401A0 (en) 2014-01-30
KR20210135003A (ko) 2021-11-11
EP2709588B1 (en) 2021-08-25
JP2020073469A (ja) 2020-05-14
ES2859784T3 (es) 2021-10-04
AU2019203400A1 (en) 2019-08-01
MX2019003340A (es) 2019-07-04
CA2836398C (en) 2021-12-14
CA2836405C (en) 2021-09-07
AU2012257492A1 (en) 2013-12-19
PL2714006T4 (pl) 2021-08-16
JP2014515038A (ja) 2014-06-26
KR102088038B1 (ko) 2020-03-13
JP2017160204A (ja) 2017-09-14
CA3034552A1 (en) 2012-11-22
WO2012156820A9 (en) 2014-02-20
MX374398B (es) 2025-03-06
JP2022105175A (ja) 2022-07-12
JP6152092B2 (ja) 2017-06-28
JP2018199701A (ja) 2018-12-20
KR20240162608A (ko) 2024-11-15
MX2013013388A (es) 2014-09-15
AU2012257490A1 (en) 2013-12-19
KR20230041081A (ko) 2023-03-23
EP2714006B1 (en) 2020-12-09
AR086409A1 (es) 2013-12-11
EP2709588A1 (en) 2014-03-26
KR20210029849A (ko) 2021-03-16
WO2012156820A1 (en) 2012-11-22
EP2714006A1 (en) 2014-04-09
CA2836398A1 (en) 2012-11-22
JP6594924B2 (ja) 2019-10-23
KR20140033408A (ko) 2014-03-18
JP7017254B2 (ja) 2022-02-08
KR20190006194A (ko) 2019-01-17
BR112013029332A2 (pt) 2021-06-01
CN109481394A (zh) 2019-03-19
KR20140045400A (ko) 2014-04-16
AU2017203470A1 (en) 2017-06-22
AU2019203067A1 (en) 2019-05-23
BR112013029336B1 (pt) 2021-11-30
MX363561B (es) 2019-03-27
AU2024216312A1 (en) 2024-10-24
KR20200028503A (ko) 2020-03-16
WO2012156822A1 (en) 2012-11-22
MX395212B (es) 2025-03-21
KR102568894B1 (ko) 2023-08-21
AU2022202402A1 (en) 2022-05-12
EA201391701A1 (ru) 2014-04-30
CA3034552C (en) 2023-02-07
KR20190117803A (ko) 2019-10-16
JP2022078222A (ja) 2022-05-24
MX2020008599A (es) 2022-08-31
CN109481394B (zh) 2023-05-05
AU2019201618A1 (en) 2019-04-18
CN110613679A (zh) 2019-12-27
JP2021001206A (ja) 2021-01-07
MX2013013369A (es) 2014-10-17
KR20200118228A (ko) 2020-10-14
AU2020210227A1 (en) 2020-08-20
PL2714006T3 (pl) 2021-08-16
JP2014513716A (ja) 2014-06-05
ZA201309264B (en) 2015-09-30
ZA201309265B (en) 2016-01-27
CN103796636A (zh) 2014-05-14
BR112013029336A2 (pt) 2020-08-11
CN103796636B (zh) 2019-04-05
DK2714006T3 (da) 2021-03-15
AR089553A1 (es) 2014-09-03
AU2020267162A1 (en) 2020-12-03
EP3977982A1 (en) 2022-04-06
CA2836405A1 (en) 2012-11-22
AU2017204182A1 (en) 2017-07-20
AU2020267162B2 (en) 2022-06-09
IL229400A0 (en) 2014-01-30
JP2020079257A (ja) 2020-05-28

Similar Documents

Publication Publication Date Title
US20250064831A1 (en) Controlled release topical testosterone formulations and methods
JP7017254B2 (ja) 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
US20150290217A1 (en) Male testosterone titration methods, male intranasal testosterone bio-adhesive gel formulations and use thereof for treating hypogonadism and trt
US20240316063A1 (en) Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
HK40018181A (en) Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
HK1196261B (en) Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
HK1263036A1 (en) Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160108

Address after: Barbados Christchurch District

Applicant after: Aiseersi Pharmaceutical Co. Ltd.

Address before: Barbados Christchurch District

Applicant before: TRIMEL PHARMACEUTICALS SRL

RJ01 Rejection of invention patent application after publication

Application publication date: 20140521

RJ01 Rejection of invention patent application after publication